Helen Louise Collins, CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 5,000 shares at $50.03 ($252K) on 2026-09-17, disclosed to the SEC on 2026-09-21.
Scheduled sale ($252k) by CHIEF MEDICAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.03 | 2,916 | $146K | 57.9% |
| 2 | $50.71 | 1,844 | $94K | 37.1% |
| 3 | $51.48 | 240 | $12K | 4.9% |
| Total | $50.35 avg | 5,000 | $252K | 100% |
| Filing → |
| ELVN | SELL | 2026-06-22 | $219K | — | Filing → |
| ELVN | SELL | 2026-05-20 | $199K | — | Filing → |
| ELVN | SELL | 2026-04-21 | $238K | — | Filing → |